Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antisense oligonucleotide therapy for proline-23-histidine autosomal dominant retinitis pigmentosa.

Current opinion in ophthalmology - 1 May 2023

Justin Grant A, Girach Aniz, Maldonado Ramiro S

Abstract excerpt

PURPOSE OF REVIEW: To discuss antisense oligonucleotide (ASON) therapy for autosomal dominant retinitis pigmentosa (adRP) caused by the proline-23-histidine (P23H) mutation in the rhodopsin gene. RECENT FINDINGS: Viral and nonviral therapies to treat adRP are currently under investigation. A promising therapeutic option is a nonviral approach using ASONs. This form of genetic therapy has demonstrated a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Histidine
Share to Oligonucleotides, Antisense

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proline

Share to Retinitis Pigmentosa

Share to Rhodopsin

Source

Identifiers

PMID: 36924362
DOI: 10.1097/ICU.0000000000000947

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antisense oligonucleotide therapy for proline-23-histidine autosomal dominant retinitis pigmentosa.PMID 36924362Read ↗

Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa.Semantic proximity Read ↗

Progress in Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa.Semantic proximity Read ↗

Allele-Specific Inhibition of Rhodopsin With an Antisense Oligonucleotide Slows Photoreceptor Cell Degeneration.Semantic proximity Read ↗

Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.Semantic proximity Read ↗

Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by mutations in <i>USH2A</i> exon 13Semantic proximity Read ↗

Gene augmentation for autosomal dominant retinitis pigmentosa using rhodopsin genomic loci nanoparticles in the P23H+/- knock-in murine model.Semantic proximity Read ↗

Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases.Semantic proximity Read ↗

Gene therapy in animal models of autosomal dominant retinitis pigmentosa.Semantic proximity Read ↗

Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations.Semantic proximity Read ↗

Effect of AAV-Mediated Rhodopsin Gene Augmentation on Retinal Degeneration Caused by the Dominant P23H Rhodopsin Mutation in a Knock-In Murine Model.Semantic proximity Read ↗

Antisense oligonucleotide allele-specific targeting of EFEMP1 in a patient-derived model of Doyne honeycomb retinal dystrophySemantic proximity Read ↗

Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.